News headlines about Ophthotech (NASDAQ:OPHT) have been trending somewhat positive this week, according to Accern. The research group identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Ophthotech earned a coverage optimism score of 0.16 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 46.3677870898304 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the headlines that may have impacted Accern’s rankings:
- Chardan Capital Reaffirms Hold Rating for Ophthotech (OPHT) (americanbankingnews.com)
- Edited Transcript of OPHT earnings conference call or presentation 1-Aug-18 12:00pm GMT (finance.yahoo.com)
- Ophthotech (OPHT) Posts Earnings Results, Beats Estimates By $0.02 EPS (americanbankingnews.com)
- Ophthotech Corp (OPHT) CEO Glenn Sblendorio on Q2 2018 Results – Earnings Call Transcript (seekingalpha.com)
- Ophthotech Corp (OPHT) Tops Q2 EPS by 2c (streetinsider.com)
Shares of Ophthotech stock traded down $0.05 on Thursday, hitting $2.41. The company had a trading volume of 131,200 shares, compared to its average volume of 451,197. The stock has a market capitalization of $90.11 million, a PE ratio of 0.76 and a beta of 1.31. Ophthotech has a twelve month low of $2.25 and a twelve month high of $4.50.
Several brokerages have commented on OPHT. ValuEngine downgraded shares of Ophthotech from a “hold” rating to a “sell” rating in a research note on Monday, July 2nd. Chardan Capital reiterated a “hold” rating and issued a $4.00 price target on shares of Ophthotech in a report on Thursday. Finally, Zacks Investment Research cut shares of Ophthotech from a “buy” rating to a “hold” rating in a report on Tuesday, July 10th. Two analysts have rated the stock with a sell rating and three have assigned a hold rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $3.67.
Ophthotech Corporation, a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. The company is developing Zimura, an inhibitor of complement factor C5, for dry and wet forms of age-related macular degeneration, a disorder of the central portion of the retina known as the macula.
Featured Story: Closed-End Mutual Funds (CEFs)
Receive News & Ratings for Ophthotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ophthotech and related companies with MarketBeat.com's FREE daily email newsletter.